Vertex Energy (VTNR) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #2 (Buy). This rating change essentially reflects an upward trend in earnings estimates -- one ...
Vertex Pharmaceuticals (NASDAQ: VRTX) is trading near a record high after climbing about 20% so far this year, and delivering a triple-digit gain over three years. So, you may be a bit hesitant about ...
Jupiter Endovascular, which was formed by Neptune Medical a little more than a year ago, shared positive results from the ...
Jupiter Endovascular today announced positive results from the first-in-human study of its Vertex pulmonary embolectomy ...
Vertex has built a billion-dollar business thanks to its expertise in treating cystic fibrosis. The biotech stock is cheaper today than it was earlier this year in relation to expected earnings. But ...
Vertex Pharmaceuticals has hit a snag in its efforts to follow up non-opioid pain reliever Journavx (suzetrigine). The Boston-based Big Biotech’s sodium channel inhibitor VX-993 failed to outpace ...
If you are eyeing Vertex and wondering whether now is the right moment to jump in, you are not alone. The company has certainly grabbed attention lately. In just the last week, the stock moved up 2.4% ...
Vertex Pharmaceuticals Inc. (($VRTX)) announced an update on their ongoing clinical study. Vertex Pharmaceuticals Inc. is conducting a Phase 3 ...
NEW YORK, May 21 (Reuters) - Schering-Plough Corp said on Wednesday it has begun two late-stage trials of its experimental boceprevir treatment for hepatitis C, lifting its shares and bringing down ...
Vertex Pharmaceuticals has built a billion-dollar cystic fibrosis business over time. But the company today may be preparing for a new era of growth, thanks to the strength of its pipeline. Vertex ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback